Immunocore Holdings (IMCR) Net Cash Flow (2023 - 2026)

Immunocore Holdings has disclosed Net Cash Flow across 4 years of filings, most recently posting -$8.9 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$8.9 million, down 170.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$36.3 million (up 90.02% YoY), and the FY2025 annual result was -$14.7 million, down 199.11% from the prior year.
• Net Cash Flow came in at -$8.9 million for Q1 2026 at Immunocore Holdings, up from -$29.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $391.0 million in Q1 2024 to a low of -$327.7 million in Q2 2024.
• The 4-year median for Net Cash Flow is $2.7 million (2025), against an average of $1.8 million.
• Peak annual rise in Net Cash Flow reached 2758.78% in 2024, while the deepest fall reached 3304.04% in 2024.
• Immunocore Holdings' Net Cash Flow stood at -$12.3 million in 2023, then plunged by 461.17% to -$69.0 million in 2024, then surged by 57.61% to -$29.3 million in 2025, then surged by 69.57% to -$8.9 million in 2026.
• The last three Net Cash Flow figures came in at -$8.9 million (Q1 2026), -$29.3 million (Q4 2025), and $2.7 million (Q3 2025), per Business Quant data.